Mineralys Therapeutics’ (MLYS) “Buy” Rating Reiterated at HC Wainwright
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $42.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 177.96% from the company’s previous close. A number of other equities […]
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $42.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 177.96% from the company’s previous close. A number of other equities […]
